Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The last piece of the financing jigsaw was put in place earlier Wednesday after it unveiled US$20mln of debt funding
It will draw down immediately US$15mln of the facility, provided by Hercules Capital
The US Food & Drug Administration gave the thumbs up overnight
The ‘buy’ call was made on valuation grounds with the stock having fallen 21% since the start of June
The deal, the second of its kind, is with an unnamed leading biopharmaceutical and is worth £750,000 over two years
The agreement provides access to another "important and very relevant" global region for genedrive, the company said
Lupuzor is currently undergoing a phase III clinical trial 200 in patients in the US, Europe and Mauritius
A tough and competitive market hit the firm's Generics business
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.